GPCR News

Post: Blog2_Post

Jan 1, 20221 min read

Addex Therapeutics CEO Tim Dyer: There is a $4-bil market opportunity in dyskinesia

Updated: Aug 23, 2022

January 2022 "Watch our CEO Tim Dyer on AlphaStreet. In his interview, Mr. Dyer provides an overview of our #allostericmodulator pipeline and the potential $4 billion market for our lead compound #dipraglurant in #PDLID (#Parkinsonsdisease levodopa-induced #dyskinesia)."

Recent Posts

See All

Emerging approaches for decoding neuropeptide transmission

November 2022 "Neuropeptides produce robust effects on behavior across species, and recent research has benefited from advances in...

Location bias contributes to functionally selective responses of biased CXCR3 agonists

November 2022 "Some G protein-coupled receptor (GPCR) ligands act as "biased agonists" that preferentially activate specific signaling...

Deciphering the signaling mechanisms of β-arrestin1 and β-arrestin2 in regulation of cancer cell...

November 2022 Deciphering the signaling mechanisms of β-arrestin1 and β-arrestin2 in regulation of cancer cell cycle and metastasis...

GPCR News

Addex Therapeutics CEO Tim Dyer: There is a $4-bil market opportunity in dyskinesia

Recent Posts

Comments